Navigation Links
NewCardio Study of QTinno Accuracy Selected for Presentation at the National Scientific Meeting of the American Society of Clinical Pharmacology and Therapeutics
Date:2/8/2011

the pharmaceutical industry. The data we will be presenting demonstrate that NewCardio's novel automated ECG selection algorithm substantially improves data quality in drug safety studies. Pharma sponsors can use our automated ECG selection technology and QTinno to increase study power, thereby reducing the risk of a failed study. Alternatively, the sponsor can reduce the number of subjects in a study without sacrificing study power, which may represent a substantial cost savings. We believe this is a powerful extension of our platform technology, and demonstrates NewCardio's ability to add value to every ECG."  

About QTinno TechnologyNewCardio's patented QTinno 3-D ECG software technology is a novel, fully automated program for evaluating QT and other timing intervals relevant for assessing drug cardiac toxicity in drug development. It provides fast, accurate and precise QT data from a broad range of challenging ECGs and enables reliable, automated identification of key cardiac events. Pharmaceutical sponsors and clinical research organizations, which are mandated by the FDA to test new drugs for potential cardiac toxicity, are expected to benefit from QTinno's faster, more accurate and less expensive assessment of cardiac status.

About the American Society for Clinical Pharmacology and Therapeutics (ASCPT)The American Society for Clinical Pharmacology and Therapeutics (ASCPT) consists of over 2,100 professionals committed to promoting and advancing the science and practice of human pharmacology and therapeutics, and is the largest professional organization serving the discipline of clinical pharmacology.

About NewCardio, Inc.NewCardio is a cardiac diagnostic and services company developing and marketing proprietary software platform technologies to provide higher accuracy to, and increase the value of, t
'/>"/>

SOURCE NewCardio, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. NewCardio Presents Results for Cardiac Safety Research Consortium Blinded Drug Safety Study
2. NewCardios Chief Technical Officer, Dr. Dorin Panescu, Named 2011 IEEE Fellow
3. NewCardio Announces Financial Results for Its 2010 Third Quarter
4. NewCardio to Present Results of QTinno Performance on Cardiac Safety Research Consortium Blinded Testing Dataset
5. NewCardio CEO Increases Equity Position
6. NewCardio Announces Financial Results for the First Half of 2010 and Commercialization Progress
7. NewCardio to Sponsor and Present at 4th Annual Cardiac Safety Assessment Summit
8. NewCardio Announces Master Services Agreement With Dedicated Phase I
9. NewCardio Leadership to Present Two Abstracts at ISCE Conference
10. Vincent W. Renz Joins NewCardio as President
11. NewCardio Announces Positive Results From Third Clinical Validation Study
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/24/2014)... July 24, 2014  IRIDEX Corporation (NASDAQ: ... second quarter 2014 financial results after the market closes ... with the release, the Company will host a conference ... Eastern Time on Thursday, July 31, 2014 ... other business developments. Interested parties may access ...
(Date:7/24/2014)... July 24, 2014 Omnicell, Inc. (NASDAQ: ... medication and supply management solutions and analytics software ... July 31, to discuss the Company,s Second Quarter ... Quarter 2014 earnings conference call and webcastWhen: ... Randall Lipps, chairman, president and chief executive officer ...
(Date:7/24/2014)... -- IGI Laboratories, Inc. (NYSE MKT: IG), a New Jersey based ... results for the second quarter ended June 30, 2014. ... of $6.5 million in the second quarter of 2014, an ... , Total revenues of $13.3 million for the six months ... same period in 2013 , Total revenues generated from ...
Breaking Medicine Technology:Omnicell to Release Second Quarter 2014 Earnings Results on July 31 2IGI Laboratories Announces Second Quarter 2014 Results 2IGI Laboratories Announces Second Quarter 2014 Results 3IGI Laboratories Announces Second Quarter 2014 Results 4IGI Laboratories Announces Second Quarter 2014 Results 5IGI Laboratories Announces Second Quarter 2014 Results 6IGI Laboratories Announces Second Quarter 2014 Results 7
... MicroCHIPS, Inc., a developer of innovative drug delivery ... Office and Trademark Office has granted U.S. Patent No. ... This patent in conjunction with U.S. Patent No. 7,070,590 ... reservoir-based medical devices used for implantable drug delivery systems. ...
... Promidian, a management consulting firm focused on ... survey findings about the increasing interest in the ... that is rapidly gaining nationwide attention for its ... care—while reducing costs. The Promidian ...
Cached Medicine Technology:MicroCHIPS Announces 35th U.S. Patent for Microreservoir-Based Drug Delivery Systems 2Promidian Survey Finds Growing Support for Patient-Centered Medical Home 2
(Date:7/27/2014)... Los Angeles, CA (PRWEB) July 27, 2014 ... of Summer Tickets at The Forum in Inglewood, California on ... new album and diehard fans can expect to hear songs from ... 5 Seconds of Summer concert in Inglewood, California at The Forum ... Find tickets starting at 10:00 a.m. today local time TicketDown.com. ...
(Date:7/27/2014)... Manchester have discovered why medication to treat asthma and pneumonia ... Medicine , show that drugs widely used to treat lung ... the UK pneumonia, which is caused by an infection, affects ... serious for babies, young children, the elderly, smokers and those ... million people in the UK are affected by asthma and ...
(Date:7/27/2014)... (PRWEB) July 27, 2014 The North ... is estimated at $1570 million in 2014, and it ... a CAGR of 4.64%. The report incorporates the factors ... detailed expectations of growth rates and projected total expenditure. ... in the global markets. Apart from the general overview ...
(Date:7/27/2014)... 27, 2014 The European Agricultural Adjuvants ... Europe with analysis and forecast of revenue. The agricultural ... around $509.4 million in 2013 to $657.1 million by ... 2018. , Browse through the TOC of the European ... the in-depth analysis provided. It also provides a glimpse ...
(Date:7/27/2014)... July 27, 2014 Metachromatic leukodystrophy ... lysosomal storage disease which is commonly listed in ... the sphingolipidoses as it affects the metabolism of ... myelin, the fatty covering which acts as an ... peripheral nervous systems. MLD involves cerebroside sulfate accumulation. ...
Breaking Medicine News(10 mins):Health News:5 Seconds of Summer Tickets at The Forum in Inglewood (Los Angeles), CA Now Available For Sale at Ticket Down 2Health News:Drugs used to treat lung disease work with the body clock 2Health News:North America Security and Surveillance Radar Market is Expected to Reach $2030 million in 2019 - New Report by MicroMarket Monitor 2Health News:North America Security and Surveillance Radar Market is Expected to Reach $2030 million in 2019 - New Report by MicroMarket Monitor 3Health News:North America Security and Surveillance Radar Market is Expected to Reach $2030 million in 2019 - New Report by MicroMarket Monitor 4Health News:North America Security and Surveillance Radar Market is Expected to Reach $2030 million in 2019 - New Report by MicroMarket Monitor 5Health News:Europe Agricultural Adjuvants Market is Expected to Reach $657.1 million in 2018 - New Report by MicroMarket Monitor 2Health News:Europe Agricultural Adjuvants Market is Expected to Reach $657.1 million in 2018 - New Report by MicroMarket Monitor 3Health News:Europe Agricultural Adjuvants Market is Expected to Reach $657.1 million in 2018 - New Report by MicroMarket Monitor 4Health News:Europe Agricultural Adjuvants Market is Expected to Reach $657.1 million in 2018 - New Report by MicroMarket Monitor 5Health News:Metachromatic Leukodystrophy Therapeutics Clinical Trials Market Review H2 2014 Report Available at LifeScienceIndustryResearch.com 2Health News:Metachromatic Leukodystrophy Therapeutics Clinical Trials Market Review H2 2014 Report Available at LifeScienceIndustryResearch.com 3Health News:Metachromatic Leukodystrophy Therapeutics Clinical Trials Market Review H2 2014 Report Available at LifeScienceIndustryResearch.com 4Health News:Metachromatic Leukodystrophy Therapeutics Clinical Trials Market Review H2 2014 Report Available at LifeScienceIndustryResearch.com 5
... at risk for the disease, as well as ways to prevent ... osteoporosis. ,1. MYTH: Only women get osteoporosis ... this condition, theres also a very significant portion of men who ... suffer from osteoporosis, accounting for 20 percent of those diagnosed with ...
... US-based Redux Beverages said it would be marketing. Well, only it was ... drink. ,In September last year it announced the launch ... illegal drug. ,Jamey Kirby, the drink's inventor, said the name ... session at 1 o'clock in the morning. ,"It's an ...
... how nerve cells signal to one another could rewrite the ... at Weill Cornell Medical College and Yale University. ... journal Science, suggests that a key cellular enzyme called dynamin ... had previously assumed. ,Dynamin has long been a ...
... and additional risk factors for heart disease may ... two , if their current treatment combines the ... amlodipine, researchers reported at the American Heart Association's ... Outcomes Research in Cardiovascular Disease and Stroke. ...
... The Health and Family Welfare Minister, Dr. Anbumani ... Nursing Personnel today , said that under the ... requires about 200,000 nursing personnel to provide comprehensive ... achieve the requirements of NRHM, State Governments have ...
... Sensitive issues, poignant emotions and subjects that are not ... body were the mainstay of the international film festival ... on its first day Saturday. , ,Brought ... Bharati Corporation, the Mac Arthur Foundation and UNESCO, the ...
Cached Medicine News:Health News:7 Common Myths About Osteoporosis 2Health News:7 Common Myths About Osteoporosis 3Health News:'Cocaine' Turns 'Censored' and Remains 'energy Drink' 2Health News:'Cocaine' Turns 'Censored' and Remains 'energy Drink' 3Health News:Study Revises Dynamin's Role in Nerve Cell Function 2Health News:Study Revises Dynamin's Role in Nerve Cell Function 3Health News:One Pill may Be Better Than Two for Treating Patients With High Blood Pressure 2Health News:One Pill may Be Better Than Two for Treating Patients With High Blood Pressure 3Health News:Film Festival on Gender Sexuality Draws Crowds 2
... The Humphrey Field Analyzer II-i series is ... examine the patient's visual field. By using ... time is reduced by up to 70%. ... compact, ergonomic design to increase patient comfort ...
... Matrix represents the latest breakthrough in ... technology, the Humphrey Matrix will help ... evaluation and assess treatment alternatives. Enhanced ... provide complete long-term glaucoma care for ...
... Proclear Tailor Made Toric soft contact lenses let ... any other soft toric lens in a lens ... level of comfort is made possible by PC ... of phosphorylcholine (PC), a substance found naturally in ...
Preference Toric quarterly planned replacement lenses are durable, easy to handle and virtually maintenance free. Meeting the needs of those suffering from astigmatism, these soft contact lenses are ...
Medicine Products: